Premium
Razoxane regimen for the treatment of psoriasis *
Author(s) -
HARPER J.I.,
COPEMAN P.W.M.,
STAUGHTON R.C.D.
Publication year - 1982
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.1982.tb02478.x
Subject(s) - regimen , medicine , psoriasis , dermatology , unit (ring theory) , family medicine , surgery , psychology , mathematics education
Razoxane [ICRF 159, 1,2‐bis(3,5‐dioxopiperazin‐I‐yl) propane] is an oral antimitotic agent, which is very effective in the treatment of psoriasis (Atherton et al. , 1980). Its efficacy in psoriasis is related to its effect on the increased epidermopoiesis and on the abnormal dermal microvasculature. Razoxane arrests the cell cycle progression only during the late pre‐mitotic (G2) or the early mitotic (M) phase of the cell cycle.